Elsevier

Life Sciences

Volume 19, Issue 5, 1 September 1976, Pages 725-731
Life Sciences

Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine

https://doi.org/10.1016/0024-3205(76)90170-3Get rights and content

Abstract

Rats administered chronic neuroleptics for 6–7 weeks-- haloperidol (2.5 mg/rat or 1 mg/kg), clozapine (25 mg/kg), or thioridazine (20 mg/kg)--after termination of chronic drug treatment exhibited greater apomorphine-induced stereotyped behavior than their saline controls. Rats treated with thioridazine or clozapine, but not haloperidol, also showed increases in locomotor activity during withdrawal. These findings indicate that behavioral supersensitivity may develop after chronic clozapine treatment as well as after chronic haloperidol.

References (19)

  • D. Tarsy et al.

    Neuropharmacology

    (1974)
  • B. Costall et al.

    Eur. J. Pharmacol.

    (1973)
  • K.M. Taylor et al.

    Brain Research

    (1971)
  • B. Westerink et al.

    Eur. J. Pharmacol.

    (1975)
  • R.C. Smith et al.

    Psychopharm. Comm.

    (1975)
  • R. Rubovits et al.
  • G. Gianutsos et al.

    Life Sci.

    (1973)
  • K.E. Moore et al.
  • R. Rubovits et al.

    Arch. Gen. Psychiat.

    (1972)
There are more references available in the full text version of this article.

Cited by (95)

  • Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity

    2021, Behavioural Brain Research
    Citation Excerpt :

    A study reported that clozapine, like aripiprazole, did not cause DRD2 up-regulation at cell levels [154]. On the other hand, several animal models showed behavioral supersensitivity caused by clozapine [155,156]. Past studies have shown that clozapine greatly improved tardive dyskinesia which was caused by previous medications [157].

  • Continuous versus extended antipsychotic dosing in schizophrenia: Less is more

    2021, Behavioural Brain Research
    Citation Excerpt :

    This exaggerated response is the most commonly used index of antipsychotic-induced dopamine supersensitivity in laboratory rodents. In rats, antipsychotic-induced dopamine supersensitivity produces robust sensitization to the psychomotor-activating effects of dopamine agonists, but also to their reward-enhancing effects [39,40,43–49]. Antipsychotic-evoked dopamine supersensitivity is often studied in otherwise neurologically intact animals, but it can also be seen in well-established animal models of schizophrenia symptoms [45].

  • 5-HT<inf>2</inf> receptors modulate the expression of antipsychotic-induced dopamine supersensitivity

    2015, European Neuropsychopharmacology
    Citation Excerpt :

    However, amphetamine-induced locomotion permits an accessible and rapid assessment of dopamine function following antipsychotic treatment. In parallel, other studies have shown that antipsychotic-induced dopamine supersensitivity is also characterized by an enhanced ability of the direct dopamine receptor agonist apomorphine to stimulate both horizontal locomotor activity and stereotyped behaviour (Asper et al., 1973; Clow et al., 1979; Gianutsos et al., 1974; Montanaro et al., 1982; Sayers et al., 1975; Smith and Davis, 1975, 1976). Finally, a question raised by our findings is whether treatment with an atypical antipsychotic would induce similar alterations in 5-HT2 receptor density and function.

  • Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function

    2015, Neuropharmacology
    Citation Excerpt :

    For instance, antipsychotic-induced dopamine supersensitivity is thought to increase the incidence of both psychosis upon treatment cessation (Chouinard et al., 1978; Tollefson et al., 1999) and movement disorders (Casey, 1995). In addition, it increases the ability of dopamine agonists to potentiate both psychomotor activity (Asper et al., 1973; Samaha et al., 2008, 2007; Smith and Davis, 1976) and operant responding for conditioned reward (CR; (Bedard et al., 2011, 2013). Finally, in animal models of antipsychotic-like effects, dopamine supersensitivity following antipsychotic treatment is linked to decreased efficacy of currently used (Samaha et al., 2008, 2007) and experimental (Gill et al., 2014) antipsychotic compounds.

  • T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats

    2012, Neuropharmacology
    Citation Excerpt :

    Also, pre-treatment with TTA-A2 did not sensitize animals to the psychomotor activating effects of amphetamine, in contrast with what was observed with haloperidol. This is potentially important because it has been hypothesized that the sensitized stimulant response produced by chronic treatment with antipsychotics (Rebec et al., 1982; Samaha et al., 2007; Smith and Davis, 1975, 1976) might reflect neurobiological changes associated with a loss of clinical efficacy (Samaha et al., 2007). Third, TTA-A2 decreased the ability of amphetamine to engage the nucleus accumbens (but not caudate putamen), as revealed by a decrease in amphetamine-induced c-fos expression in this region.

View all citing articles on Scopus
View full text